Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Maintain ADD on Dr. Reddy's Labs - Good quarter, lower SG&A cost is encouraging - HDFC Securities

Posted On: 2020-10-29 05:49:33

Ms. Bansi Desai,, Institutional Research Analyst, HDFC Securities

Dr. Reddys' Q2 Rev/PAT beat estimates by 4%/20% driven by strong growth across markets and lower tax rate. Tight control on SG&A cost (-208bps QoQ) is noteworthy given sequential increase in marketing spends and integration of Wockhardt portfolio in the quarter. The business outlook remains strong with multiple triggers such as upsides from Covid portfolio (Sputnik V vaccine, Favipiravir trial in US) and complex approvals/launches in the US (gVascepa, Copaxone, gNuvaring); however, launch timelines for these remain uncertain. We expect core business performance to remain strong aided by structural tailwinds in API business, strong launch momentum in US, traction in EU business and ramp-up in Wockhardt portfolio. Our estimates largely remain unchanged and we marginally increase our TP to Rs5,390 (from Rs5,375 earlier). Maintain ADD.

Strong traction across markets: Revenues grew by 20% YoY led by strong growth in India (+21% YoY, Wockhardt integration, Covid drugs), PSAI (+20% YoY, services biz, currency gains), Europe (+36% YoY, new launches, currency gains) and US (+6% QoQ, new launches). EBIDTA margins were steady at 25.2% (-21bps QoQ) as lower gross margins (-211 QoQ, lower export incentive, product mix, forex) were offset by lower SG&A cost (-208bps, productivity gains). Adjusting for one offs, PAT came at Rs8.4bn aided by lower tax rate (11%, DTA led).

US pipeline holds promise: Limited competition products in pipeline such as gKuvan (TA in place), gVascepa (preparing for launch), gNuvaring and gCopaxone (uncertain timelines) add longer term growth visibility to the US business. US pipeline consist of 92 pending ANDA (50 Para IVs, 26 FTFs). This, along with strong launch momentum (30+ launches in FY21) will drive 15% revenue CAGR over FY20-23e.

Key call takeaways: a) gVascepa - launch timelines not disclosed; b) Sputnik V - approval is contingent on outcome of global trials, Phase 3 trial in India (1,400 patients) to end by May 21, plans 100mn doses in a phased manner; c) Wockhardt integration - progressing well; d) Net debt: Rs1.4bn, ETR at 25% for FY21; e) Rituximab - Phase 3 trial progressing well; f) M&A opportunities - will continue to evaluate.

Valuation and risks: We maintain ADD rating and increase our SOTP based target price to Rs 5,390. Our target price is based on 22x Sep 22 EPS and NPV of Rs384/share for gRevlimid. Key risks: delay in key approvals; higher price erosion in the US; adverse outcome on drug price fixing lawsuit in US; and delay in turnaround of Wockhardt portfolio.

Shares of DR.REDDY's LABORATORIES LTD. was last trading in BSE at Rs.4942.45 as compared to the previous close of Rs. 4949.8. The total number of shares traded during the day was 47875 in over 5865 trades.

The stock hit an intraday high of Rs. 5041.6 and intraday low of 4892.8. The net turnover during the day was Rs. 238162680.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Auto Sector - Monthly Volume Round-up - Nov 20 - Reliance Securities

What do brokerages say on Burger King India Limited's IPO?

The Phoenix Mills - Potential fund infusion may usher in growth - ICICI Securities

Godrej Agrovet - Beneficiary of 60% increase in palm oil prices - ICICI Securities

Automobiles (wholesale) - Wholesale dispatches rise amidst modest retail trends - ICICI Securities

Oil & Gas - Sector Update - Dec 2020 - ICICI Direct

Phoenix Mills (Buy): Asset monetisation at favourable terms... - ICICI Direct

Aditya Makharia's views on November Auto Sales Number for November 2020 - HDFC Securities

Burger King India - IPO Review - ICICI Direct

Quant Pick - LIC Housing Finance - ICICI Direct

Tech Mahindra - Analyst Meet Update - ICICI Direct

Gladiator Stocks - Crompton Greaves Consumer Electricals - ICICI Direct

Derivatives Monthly Outlook - Nifty support at 12800 for ongoing momentum...

Quant Pick - Sun Pharmaceuticals - ICICI Direct

Monetary Policy - Expectation from YES Securities

Sector Update on Asset Management Companies - Subdued but improvement expected - HDFC Securities

Pre Monetary Policy View - Dec, 2020 - Lakshmi Iyer, President and CIO (Debt) & Head Products, Kotak Mutual Fund

Maintain REDUCE on Siemens - Smart recovery priced in - HDFC Securities

Banking Sector Credit Trends - Growth continues to moderate - HDFC Securities

Q2 FY21 GDP: Light at the end of the tunnel - YES Securities

Siemens - Q4 FY20 Result Update - YES Securities

Super action in Home Loans - SBIN, ICICIBC, AXSB, HDFC and LICHF gaining share - YES Securities

Polymer price tracker - Dec 1, 2020 - PVC prices continue to tread higher - ICICI Securities

Bajaj Finance - Company Update - Dec 2020 - ICICI Direct

Siemens Ltd - Healthy revival in orders and margins - ICICI Securities

Covid Recovery Pulse - Nov 30, 2020 - Festive positivity continues in auto retails, e-way bill generation improves...

Derivatives Weekly View (November 27): Momentum expected to continue in broader markets with Nifty support at 12800...

Derivatives Strategy - Positional Option - ICICI Direct

Preview on RBI Monetary Policy - December 2020 - Shanti Ekambaram, Group President - Consumer Banking, Kotak Mahindra Bank

10 things you should know about Burger King India Limited

Views of HDFC Securities and Acuité Ratings & Research on Q2FY21 GDP Numbers

Rollover Report for November 2020 - December 2020: Angel Broking

Initiating Coverage on Godrej Properties - The housing factory - HDFC Securities

Burger King IPO - Angel Broking

Rollover Analysis - Record foreign inflows pushes Nifty to 13k - YES Securities

Ceramic tiles industry - Market share gains sustain for top branded players - ICICI Securities

Gas sector - CGD: Competition to hit margins, volumes and lead to derating - ICICI Securities

Cement - Prices resilient in Q3; consensus upgrades to continue - ICICI Securities

Specialty chemicals - Price trend in Sep-20 - ICICI Securities

Timken India - Q2FY21 Company Update - ICICI Direct

Upgrade in target price of IDFC First Bank - Angel Broking

Laurus Labs stake acquisition in Richore Lifesciences - Angel Broking

Shares of Lakshmi Vilas Bank (LVB) suspended from trading - Angel Broking

Initiating Coverage on Sundram Fasteners - Fastening growth - HDFC Securities

Astral Poly Technik - Scalability to further improve with storage tanks foray - ICICI Securities

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019